GELTEX RECEIVES $2 MIL. COMMERCE DEPT. ATP GRANT
Executive Summary
GELTEX RECEIVES $2 MIL. COMMERCE DEPT. ATP GRANT to develop nonabsorbable therapies for infectious diseases, the company announced Nov. 21. Under the three-year Advanced Technology Program grant, Waltham, Mass.-based Geltex will develop polymers that act in the gastrointestinal tract that are not absorbed into the blood stream. The company said it will target Crytosporidium parvum and human rotovirus pathogens in the initial stages of the ATP grant.